NEW YORK, Nov. 11 (GenomeWeb News) - Agilent Technology's life sciences and chemical analysis unit, which sells the company's genomics and proteomics product lines, had revenue growth of 10 percent for the quarter ending Oct. 31, the company reported today.
"LSCA shows few signs of slowing from its recent double-digit growth trend," the company said in a statement.
Agilent's Life Sciences and Chemical Analysis unit had $366 million in orders for the quarter, up 10 percent over $333 million for the year-ago period. The unit's revenues were $352 million, up 10 percent over $321 for the year-ago quarter.
The unit had a profit of $58 million, compared to $53 million for the year-ago period.
Revenue for the life-sciences segment grew 11 percent, while chemical analysis had 9 percent growth year over.
Overall, Agilent orders were 8 percent down for the quarter compared to last year's period, while revenues were up 9 percent to $1.8 billion from $1.7 billion over the same period last year. Income from operations was $173 million for the quarter, up 42 percent over the $71 million for the year-ago quarter.
The company spent $228 million on research and development in the period, up 5 percent from the $122 million in the year-ago quarter.
Agilent reported cash and cash equivalents of $2.3 billion on hand as of Oct. 31.